Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

Hao-Wen Sim,Elizabeth H Barnes,Zarnie Lwin,Mark Rosenthal,Helen Wheeler,Eng-Siew Koh,Matthew Foote,Lauren Fisher,Robyn Leonard,Merryn Hall,John Simes,Mustafa Khasraw

Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).

2019

Hao-Wen Sim
Elizabeth H Barnes
Zarnie Lwin
Mark Rosenthal
Helen Wheeler
Eng-Siew Koh
Matthew Foote
Lauren Fisher
Robyn Leonard
Merryn Hall
John Simes
Mustafa Khasraw

2042Background: The VERTU trial (ANZCTR #ACTRN12615000407594) compared Arm A (standard of care) = RT (60Gy/30 fractions) + TMZ (75mg/m2 daily) followed by TMZ (150–200mg/m2 D1–5) every 28 days for ...

Keywords:

Glioblastoma
Temozolomide
Oncology
Radiation therapy
Veliparib
Pathology
Quality of life
Internal medicine
Medicine
standard of care
newly diagnosed
Physical therapy
health related quality of life

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations